Short description
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases.
Description
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Vancouver, British Columbia, Canada, North America
Founded on
January 1, 2017
Exited on
May 3, 2019
Went public on
May 3, 2019
Stock symbol
NGENF
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$1230 - 4560
Sign in for full access
Investors
Nopepepe, Noaccessforu, Noway Youcantaccess
Sign in for full access
Founders
Brian McAlister, Harold Martin Punnett, William Joseph Radvak